术后淋巴结状态指导局部进展期胃癌围手术期化疗完成
该多中心回顾性研究纳入441例肿瘤退缩分级为2或3的局部进展期胃癌患者,比较完成与未完成全部围手术期化疗周期者的生存。整体上完成化疗与3年OS和RFS无显著差异,但在ypN0亚组中完成化疗显著改善3年OS和RFS,ypN1-3亚组则无差异,交互作用显著。
要点
- 肿瘤退缩不良的LAGC患者中,完成围手术期化疗的生存获益因ypN状态而异。
- ypN0患者完成化疗与3年OS和RFS显著改善相关。
- ypN1-3患者完成化疗未显示显著生存获益。
核心结论
- 在肿瘤退缩不良的LAGC患者术后决策背景下,完成围手术期化疗与生存的关联在ypN亚组间存在异质性,需前瞻性验证。
研究设计与样本
- 多中心回顾性研究,纳入中国三家教学医院接受围手术期化疗和根治性切除、肿瘤退缩分级为2或3的LAGC患者441例。
- 采用重叠权重比较完成全部化疗周期组与未完成组的3年OS和RFS。
主要发现
- 441例肿瘤退缩不良患者中239例(54.2%)完成全部围手术期化疗周期。
- 加权后,完成组与未完成组的3年OS(67.3% vs. 58.4%,P=0.122)和RFS(58.4% vs. 51.9%,P=0.293)无显著差异。
- ypN0亚组中,完成化疗显著改善3年OS(89.6% vs. 65.0%,P=0.002)和RFS(79.5% vs. 56.7%,P=0.004)。
- ypN1-3亚组中,完成化疗与3年OS(58.1% vs. 55.7%,P=0.788)和RFS(49.7% vs. 49.8%,P=0.892)无显著关联,交互作用P值分别为0.012和0.016。
临床怎么用
- 对于肿瘤退缩不良的LAGC患者,术后可依据ypN状态个体化决策是否完成围手术期化疗全部周期。
- ypN0患者完成全部化疗周期可能带来生存获益,ypN1-3患者需权衡完成化疗的必要性。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative chemotherapy is an important treatment option for resectable locally advanced gastric cancer (LAGC). However, completing planned cycles remains challenging for patients. This study aimed to investigate the effect of treatment completion on the survival of patients with poor tumor regression following perioperative chemotherapy. METHODS: This multicenter retrospective study reviewed the data of patients with LAGC who underwent perioperative chemotherapy and curative resection and had a tumor regression grade of 2 or 3 (i.e., at least 10% residual tumor cells in surgical specimens) at three teaching hospitals in China. To evaluate the impact of completing all cycles of perioperative chemotherapy on the 3-year overall survival (OS) and recurrence-free survival (RFS), patients who completed all treatment cycles were compared with those who did not, using overlap weighting. RESULTS: A total of 441 poor responders were included, of whom 239 (54.2%) completed all cycles of perioperative chemotherapy. After weighting, no significant differences were found in the 3-year OS (67.3% vs. 58.4%, P = 0.122) and RFS (58.4% vs. 51.9%, P = 0.293) between the complete and incomplete groups. However, completion of perioperative chemotherapy was significantly associated with improvements in 3-year OS (89.6% vs. 65.0%, P = 0.002) and RFS (79.5% vs. 56.7%, P = 0.004) in the ypN0 subgroup, but not in the ypN1-3 subgroup (3-year OS: 58.1% vs. 55.7%, P = 0.788; 3-year RFS: 49.7% vs. 49.8%, P = 0.892), with a significant interaction effect (P = 0.012 and 0.016, respectively). Several sensitivity analyses, including a landmark analysis, confirmed the robustness of these results. CONCLUSION: The association between completion of perioperative chemotherapy and survival appeared to be heterogeneous across ypN subgroups among patients with LAGC with poor response in a postoperative decision context, highlighting the need for prospective validation.
引用
- Wu YX, Huang ZN, Li YF, et al. Post-surgical lymph node status guides perioperative chemotherapy completion for locally advanced gastric cancer. Surg Endosc. 2026. PMID: 42209861. doi:10.1007/s00464-026-12811-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。